Cellectar believes that CLR1404 does not entail the development risks typically associated with early stage cancer therapeutics for the following reasons:

• CLR1404 is cleared from non-cancerous cells and will be given to patients in sub-pharmacological doses, resulting in an improved safety profile compared to chemotherapy.
• CLR1404 does not rely on inhibition or enhancement of a specific pathway; it works through cellular accumulation and cancer-selective retention.
• To date, CLR1404 has shown universal retention in all tumor models studied (n = 42), making the molecule potentially effective in numerous cancer types as compared to type-specific therapies.  Click here for the full list.
• CLR1404 is a small molecule which is easily characterized and synthesized and is therefore not subject to scale-up and manufacturing risks typically associated with large molecules such as monoclonal antibodies.
• CLR1404 is a completely new delivery mechanism, but is paired with a proven and effective radioisotope (Iodine-131) for therapy.
• CLR1404 has already been used in several physician-sponsored studies with positive preliminary safety and tolerance profiles and accumulation in lung cancers of human patients as measured by SPECT and PET/CT imaging.

Manufacturing

Quality Systems

In-licensing

Opportunity to in-license.